Migraine prophylaxis

Medical Journal of Australia

Volumn 189, Issue 5, 2008, Pages 283-288

  Stark, Richard J ^a,b   Stark, Catherine D ^c  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CANDESARTAN; CLONIDINE; CYPROHEPTADINE; DIHYDROERGOTAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERGOTAMINE; ETIRACETAM; FROVATRIPTAN; GABAPENTIN; LAMOTRIGINE; LIDOCAINE; LISINOPRIL; METHYSERGIDE; METOPROLOL; NARATRIPTAN; PIZOTIFEN; PLACEBO; PREDNISOLONE; PREDNISONE; PROPRANOLOL; SUMATRIPTAN; TOPIRAMATE; TRIPTAN DERIVATIVE; VALPROIC ACID; VERAPAMIL;

ANKLE EDEMA; ANTICHOLINERGIC SYNDROME; ARTICLE; AUSTRALIA; BRADYCARDIA; CHRONIC DAILY HEADACHE; CHRONIC PAIN; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONFUSION; CONSTIPATION; COUGHING; DECREASED APPETITE; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DREAM; DROWSINESS; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPILEPSY; EVENING DOSAGE; FATIGUE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEART MUSCLE CONDUCTION DISTURBANCE; HEMATOLOGIC DISEASE; HUMAN; HYPERKALEMIA; HYPOTENSION; LEG CRAMP; LIVER DYSFUNCTION; MENSTRUAL MIGRAINE; MIGRAINE; MIGRAINE WITH AURA; NAUSEA; NEPHROLITHIASIS; PARESTHESIA; POSITIONAL DIZZINESS; RETROPERITONEAL FIBROSIS; SEDATION; SIDE EFFECT; SOMNOLENCE; TERATOGENICITY; TRANSFORMED MIGRAINE; URINE RETENTION; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

AUSTRALIA; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; GLUCOCORTICOIDS; HUMANS; MIGRAINE DISORDERS;

EID: 53349090960     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb02028.x     Document Type: Article

References (42)

1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002; 346: 257-270.
2. Durham PL. CGRP-receptor antagonists - a fresh approach to migraine therapy? N Engl J Med 2004; 350: 1073-1075.
3. Olesen J, Diener H-C, Husstedt IW, et al. Calcitonin gene-related peptice receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350: 1104-1110.
4. Ho TW, Mannix LK, Fan X, et al; MK-0974 Protocol 004 study group. Randomized controlled trial of an oral CGRP antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70: 1304-1312.
5. Therapeutic guidelines. Neurology version 3, 2007. Melbourne: Therapeutic Guidelines Ltd, 2007.
6. Silberstein SD, Goaclsby PJ. Migraine: preventive treatment. Cephalaigia 2002; 22: 491-512.
7. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 754-762.
8. Members of the task force: Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol 2006; 13: 560-572.
9. Stark RJ, Valenti L, Miller GC. Management of migraine in Australian general practice. Med J Aust 2007; 187: 142-146.
10. National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Appendix B: Designation of levels of evidence. Canberra: NHMRC, 1999. http://www.nhmrc.gov.au/publications/synopses/cp30syn.htm (accessed Jul 2008).
11. Brandes JL, Saper JR, Diamond M, et al; MIGR-002 Study Group. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291: 965-973.
12. Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61: 490-495.
13. Storey JR, Calder CS, Hart DE, Potter DL. Topamax in migraine prevention: a double-blind placebo controlled study. Headache 2001; 41: 968-975.
14. Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004; (3): CD003226.
15. Diener HC, Tfelt-Hansen P, Dahlof C, et al. Topiramate in migraine prophylaxis - results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251: 943-950.
16. Diener HC, Agosti R, Allais G, et al. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2007; 6: 1054-1062.
17. Tronvik E, Stovner LJ, Helde GST, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003; 289: 65-69.
18. Schrader H, Stovner LJ, Helde GST, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322: 19-22.
19. Tronvik E, Stovner LJ, Schrader H, Bovim G. Involvement of the renin-angiotensin system in migraine. J Hypertens Suppl 2006; 24: S139-S143.
20. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41: 119-128.
21. Blumenfeld A. Botulinum toxin type A as an effective prophylactic treatment in primary headache disorders. Headache 2003; 43: 853-860.
22. Goadsby PJ. Squeezing life into botulinum toxin A in migraine: imploding versus exploding pain [editorial]. Pain 2006; 125: 206-207.
23. Jakubowski M, McAllister PJ, Bajwa ZH, et al. Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain 2006; 125: 286-295.
24. Castillo J, Munoz P, Guitera V, et al. Epidemiology of chronic daily headache in the general population. Headache 1999; 39: 190-196.
25. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996; 47: 871-875.
26. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-746.
27. Limmroth V, Katsarava Z, Fritsche G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002; 59: 1011-1014.
28. Diener H-C, Limmroth V, Katsarava Z. Medication-ove ruse headache. In: Goaclsby PJ, Silberstein SD, Dodick DW, editors. Chronic daily headache for clinicians. Hamilton, Ontario: BC Decker, 2005.
29. Headache Classification Subcommittee of the International Headache Society The international classification of headache disorders. 2nd ed. Cephalalgia 2004; 24 Suppl 1: 9-160.
30. Mathew NT. Amelioration of ergotamine withdrawal with naproxen. Headache 1987; 27: 130-133.
31. Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia 2000; 20: 107-113.
32. Pageler L, Katsarava Z, Diener HC, Limmroth V. Prednisone vs. placebo in withdrawal therapy following medication overuse headache. Cephatalgia 2008; 28: 152-156.
33. Williams DR, Stark RJ. Intravenous lignocaine (liclocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia 2003; 23: 963-971.
34. Lotkowski S, Silberstein SD, Rosen N. Intravenous liclocaine for chronic daily headache [abstract]. Headache 2005; 45: 831.
35. Diener H-C, Bussone G, van Oene JC, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2007; 27: 814-823.
36. Silberstein SD, Lipton RB, Doclick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 2007; 47: 170-180.
37. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004; 63: 261-269.
38. Newman L, Mannix LK, Landy S, et al. Naratriptan as prophylaxis for menstrually associated migraine: a randomized, double-blind, placebo controlled study. Headache 2001; 41: 248-256.
39. Evans RW, Lipton RB. Topics in migraine management. A survey of headache specialists highlights some controversies. Neurol Clin 2001; 19: 1-21.
40. Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005; 76: 1730-1732.
41. D'Andrea G, Granella F, Cadaldini M, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999; 19: 64-66.
42. Brighina F, Palermo A, Aloisio A, et al. Levetiracetam in the prophylaxis of migraine with aura: a 6-month open-label study. Clin Neuropharmacol 2006; 29: 338-342.